
    
      CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or
      refractory acute B lymphoblastic leukemia. CD19 and CD22 are proteins usually expressed on
      the surface of the B leukemia cells. The dual specificity CAR enables the T-cells to
      recognize and kill the tumor cell through recognition of CD19 and CD22.
    
  